Cervical Cancer Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

Cervical cancer is a malignancy arising from the cells lining the cervix — the lower, narrow portion of the uterus connecting to the vagina. It is the fourth most common cancer in women worldwide, with approximately 660,000 new cases and 350,000 deaths annually (WHO, 2022). Over 95% of cervical cancers are caused by persistent infection with high-risk strains of the human papillomavirus (HPV), particularly types 16 and 18. The disease is largely preventable through HPV vaccination and treatable when detected early through cervical screening (Pap smear and HPV testing).

Cervical cancer develops in two main histological types: squamous cell carcinoma (accounting for 70–80% of cases, arising from the squamocolumnar junction) and adenocarcinoma (20–25%, arising from glandular cells). Less common subtypes include adenosquamous carcinoma, neuroendocrine carcinoma, and others. The disease progresses through precancerous stages (CIN 1–3 / HSIL) before becoming invasive, providing an opportunity for curative intervention at the precancerous stage.

Treatment strategy is determined by the FIGO stage of the disease (IA1 through IVB), patient's age, desire for fertility preservation, overall health, and nodal/vascular involvement. Surgery is the primary treatment for early-stage disease (stages IA–IIA); chemoradiotherapy (concurrent cisplatin-based chemotherapy with external beam radiotherapy and brachytherapy) is standard for locally advanced disease (stage IIB and above).

Cervical cancer surgery addresses the following conditions along the spectrum from precancerous change to invasive carcinoma:

• CIN 2/3 (Cervical Intraepithelial Neoplasia, high-grade): Precancerous squamous lesions — treated with LEEP or cone biopsy to prevent progression to invasive cancer
• AIS (Adenocarcinoma in Situ): Glandular precancerous lesion requiring cone biopsy with negative margins; hysterectomy often advised after childbearing complete
• Stage IA1 — Microinvasive squamous carcinoma: Invasion ≤3 mm depth, no lymphovascular invasion — treated with LEEP/cone or simple hysterectomy
• Stage IA2: Invasion 3.1–5 mm — modified radical hysterectomy with pelvic lymph node dissection
• Stage IB1–IB2 and IIA1: Clinically visible localised tumour ≤4 cm — radical hysterectomy (Wertheim's hysterectomy) with pelvic lymphadenectomy
• Stage IB3 and IIA2: Tumour >4 cm — primary chemoradiotherapy preferred in most centres; selected cases may undergo surgery
• Recurrent cervical cancer: Following radiotherapy, pelvic exenteration (removal of bladder, rectum, and uterus) may be curative in highly selected cases with central pelvic recurrence

Surgical eligibility depends on the FIGO stage, lymph node status, patient fitness for major surgery, and fertility intentions. Ideal candidates for primary surgery are women with early-stage disease (IA1–IIA1), no imaging evidence of pelvic sidewall extension, no positive pelvic or para-aortic lymph nodes on imaging, good performance status (ECOG 0–1), and no severe comorbidities that would preclude general anaesthesia.

Fertility-sparing candidates (radical trachelectomy): Women under 45 with strong desire to preserve fertility, tumour ≤2 cm, squamous or usual-type adenocarcinoma, FIGO stage IA1–IB1, and no lymphovascular space invasion or lymph node involvement on preoperative assessment. MRI of the pelvis is essential to measure distance between tumour and internal os.

Women NOT suitable for primary surgery:

• FIGO stage IIB and above (concurrent chemoradiotherapy is standard)
• Bulky tumours >4 cm (IB3/IIA2) — some centres still offer surgery but evidence favours chemoradiotherapy
• Positive pelvic or para-aortic nodes on PET-CT (upstages disease and favours systemic therapy)
• Medical comorbidities (severe cardiac, renal, or pulmonary disease) precluding major surgery

1. LEEP (Loop Electrosurgical Excision Procedure) / LLETZ: An outpatient procedure using a thin wire loop carrying electrical current to excise precancerous cervical tissue under local anaesthesia. Takes 10–15 minutes. Used for CIN 2/3 and early microinvasive disease. Has a 90–95% cure rate for high-grade precancerous lesions.

2. Cone biopsy (cold knife conisation): A cone-shaped wedge of cervical tissue is removed under general or spinal anaesthesia. Provides larger margins than LEEP; preferred for AIS and deeper lesions. Also fertility-preserving for very early invasive disease.

3. Simple (total) hysterectomy: Removal of the uterus and cervix, preserving the parametria and upper vagina. Used for CIN 3 / AIS after childbearing complete, Stage IA1 without LVSI. Performed laparoscopically, robotically, or via open laparotomy.

4. Modified radical hysterectomy (Type II / Piver-Rutledge): Removes uterus, cervix, medial parametria, and upper 1–2 cm of vagina, along with pelvic lymph nodes. For Stage IA2.

5. Radical (Wertheim's) hysterectomy (Type III): The gold standard for Stage IB1–IIA1. Removes uterus, cervix, entire parametria, upper 2–3 cm of vagina, and bilateral pelvic lymph nodes. Ovaries may be conserved in premenopausal women with squamous histology. Can be performed open, laparoscopically, or with robotic assistance; multiple randomised trials favour open surgery (LACC trial) for oncological safety in invasive cancer.

6. Radical trachelectomy: Fertility-preserving procedure removing the cervix and parametria while leaving the uterine body in situ. A cervical cerclage is placed. Allows future pregnancy via IVF or spontaneous conception. Best outcomes in tumours ≤2 cm; 5-year survival comparable to radical hysterectomy in selected patients.

7. Sentinel lymph node biopsy (SLN): Increasingly used in early-stage disease to map and selectively remove sentinel nodes, reducing the morbidity of full pelvic lymphadenectomy (particularly lymphoedema).

Surgery offers excellent cure rates in early-stage cervical cancer with the potential for fertility preservation and avoidance of radiotherapy's late effects on bowel, bladder, and sexual function.

• Stage IA1: Near-100% 5-year survival with LEEP/cone biopsy or simple hysterectomy
• Stage IA2–IB1: 5-year overall survival 80–93% with radical hysterectomy and negative nodes
• Stage IB2–IIA: 5-year survival 70–85% with surgery; outcomes similar to chemoradiotherapy in randomised trials
• Radical trachelectomy: Approximately 95% 5-year disease-free survival in tumours ≤2 cm; live birth rate ~50–70% in women who attempt pregnancy
• Avoidance of radiotherapy complications: Surgery avoids chronic radiation cystitis, proctitis, vaginal stenosis, and secondary malignancies associated with pelvic irradiation
• Ovarian preservation: Possible in young women with squamous histology, avoiding surgical menopause

Risks vary considerably by extent of surgery. Minor procedures (LEEP, cone biopsy) carry minimal risk; radical hysterectomy is a major operation with recognised complication rates.

Immediate surgical risks:

• Haemorrhage requiring transfusion (1–5% for radical hysterectomy)
• Urinary tract injury — ureteral or bladder injury (1–3%); more common with wide parametrial resection
• Bowel injury (rare, <1%)
• Anaesthetic complications
• Wound infection, pelvic abscess, lymphocele formation

Long-term complications:

• Bladder dysfunction: Neurogenic bladder requiring self-catheterisation in 10–15% following radical hysterectomy — due to disruption of pelvic autonomic nerves. Nerve-sparing techniques reduce this risk
• Lymphoedema: Lower limb swelling following pelvic lymphadenectomy (10–20%); sentinel node biopsy reduces risk
• Vaginal shortening / dryness: Can impact sexual function; managed with dilators and topical oestrogen
• Premature cervical insufficiency: Following cone biopsy or LEEP — risk of mid-trimester pregnancy loss; cerclage may be required

After LEEP / Cone biopsy: Outpatient or overnight stay. Light bleeding and discharge for 2–4 weeks. Avoid intercourse, tampons, and heavy exercise for 4 weeks. Follow-up cervical smear and HPV test at 6 months to confirm clearance of disease.

After radical hysterectomy: Hospital stay of 3–7 days. Urinary catheter for 1–7 days (longer with bladder neuropathy). Drains removed before discharge. Full activity recovery takes 6–8 weeks. Return to work at 4–8 weeks. Sexual activity may resume at 6–8 weeks if wounds are healed.

Oncological surveillance: Standard follow-up protocol post-surgery:

• 3-monthly clinical reviews for years 1–2 (highest recurrence risk)
• 6-monthly reviews for years 3–5
• Annual review thereafter
• Vaginal vault cytology at 6 and 18 months
• CT/PET imaging only if symptomatic or clinically indicated
• Symptoms requiring urgent review: vaginal bleeding, leg pain/swelling, haematuria, pelvic pain

The cost of cervical cancer surgery varies substantially by procedure complexity, country, hospital accreditation, and whether reconstruction or additional treatment is needed.

• LEEP / Cone biopsy — India: USD 300–800
• LEEP / Cone biopsy — USA: USD 2,000–5,000 (without insurance)
• Radical hysterectomy — India: USD 2,500–6,000
• Radical hysterectomy — Thailand: USD 5,000–10,000
• Radical hysterectomy — UK (private): GBP 12,000–22,000
• Radical hysterectomy — USA: USD 20,000–50,000+

Additional cost factors: pelvic lymph node dissection, sentinel node mapping with radiotracer/fluorescence, robotic-assisted surgery (typically adds 20–30% to total cost), pathology and frozen section fees, neuropathology, post-operative adjuvant chemoradiotherapy if indicated, and ongoing surveillance imaging. Most international health insurance policies cover medically indicated cancer surgery; verify pre-authorisation requirements.

Surgery is not the only curative option for cervical cancer — treatment modality is strongly stage-dependent:

• Concurrent chemoradiotherapy (CRT): External beam pelvic radiotherapy with weekly cisplatin + intracavitary brachytherapy. Standard of care for Stage IIB–IVA; equivalent outcomes to surgery for Stage IB–IIA in randomised trials (with higher late toxicity to bladder and bowel)
• Brachytherapy alone: Intracavitary radiation for very early microinvasive lesions in patients unfit for surgery
• Immunotherapy: Pembrolizumab (anti-PD-1) is now approved as first-line treatment combined with chemotherapy for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826 trial)
• Targeted therapy: Bevacizumab (anti-VEGF) added to platinum-doublet chemotherapy improves survival in metastatic disease
• Active surveillance: Not appropriate for confirmed invasive cervical cancer; only considered for CIN 1 (low-grade) precancerous lesions that frequently regress spontaneously
• Prevention (HPV vaccination): The most effective long-term strategy — 9-valent HPV vaccine prevents up to 90% of cervical cancers. WHO recommends vaccination at age 9–14 before sexual debut